Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective (Q56864516)

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Antineoplastic effect of mer-trichlorobisdimethylsulphoxideaminorutheniumIII against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4].

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Water-Soluble Ruthenium(III)-Dimethyl Sulfoxide Complexes: Chemical Behaviour and Pharmaceutical Properties

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium antimetastatic agents

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium complexes can target determinants of tumour malignancy

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium Anticancer Compounds: Challenges and Expectations

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Recent developments in ruthenium anticancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium and Other Non-Platinum Anticancer Compounds

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Metal-based antitumour drugs in the post-genomic era: what comes next?

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Linking the future of anticancer metal-complexes to the therapy of tumour metastases

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Antitumor activity of imidazolium-bisimidazole-tetrachlororuthenate (III). A representative of a new class of inorganic antitumor agents

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Efficacy of 5-FU Combined to Na[trans-RuCl(4)(DMSO)Im], A Novel Selective Antimetastatic Agent, on the Survival Time of Mice With P388 Leukemia, P388/DDP subline and MCa Mammary Carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an anti-metastatic ruthenium complex

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

A categorization of metal anticancer compounds based on their mode of action

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Biophysical analysis of natural, double-helical DNA modified by anticancer heterocyclic complexes of ruthenium(III) in cell-free media

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The status of platinum anticancer drugs in the clinic and in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Gemcitabine/carboplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Non-platinum chemotherapeutic metallopharmaceuticals

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium complexes as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Antitumour metal compounds: more than theme and variations

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium-based chemotherapeutics: are they ready for prime time?

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Noble metals in medicine: Latest advances

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)2Cl2] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)2Cl2].

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ga3+ as a mechanistic probe in Fe3+ transport: characterization of Ga3+ interaction with FbpA.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Effect of gallium on the tyrosyl radical of the iron-dependent M2 subunit of ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Rates and Mechanisms of Substitution in Inorganic Complexes in Solution

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(η6-p-cymene)Cl2(pta)]

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy)2(N--N)]Cl2 with N--N=bpy, phen, dpq, dppz, and dppn

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Catalytic organometallic anticancer complexes

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Synthesis, structures, cellular uptake and apoptosis-inducing properties of highly cytotoxic ruthenium-Norharman complexes.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

DNA binding and biological activity of some platinum(II) intercalating compounds containing methyl-substituted 1,10-phenanthrolines.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Antagonizing STAT3 dimerization with a rhodium(III) complex

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Redox behavior of tumor-inhibiting ruthenium(iii) complexes and effects of physiological reductants on their binding to GMP

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Probing the stability of serum protein–ruthenium(III) drug adducts in the presence of extracellular reductants using CE

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

97Ru-transferrin uptake in tumor and abscess.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Transferrin as a metal ion mediator

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The intracellular trafficking pathway of transferrin

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Molecular control of vertebrate iron homeostasis by iron regulatory proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The Interaction of the Antitumor Complexes Na[trans-RuCl(4) (DMSO)(Im)] and Na[trans-RuCl(4)(DMSO)(Ind)] With Apotransferrin: a Spectroscopic Study

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Influence of an anti-metastatic ruthenium(iii) prodrug on extracellular protein–protein interactions: studies by bio-layer interferometry

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III).

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Albumin binding and ligand-exchange processes of the Ru(III) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Investigating the ruthenium metalation of proteins: X-ray structure and Raman microspectroscopy of the complex between RNase A and AziRu

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Comparison of the Antiproliferative Activity of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Impact of albumin on drug delivery--new applications on the horizon.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Preparation and metabolism of a cisplatin/serum protein complex

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Cisplatin binding sites on human albumin.

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

The Discovery and Development of Cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Transferrin-cisplatin specifically deliver cisplatin to HepG2 cells in vitro and enhance cisplatin cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Metal-based drugs that break the rules

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

1 reference

https://api.crossref.org/works/10.1002%2FEJIC.201600986

7 January 2021